Inspire Medical Systems (NYSE:INSP) Reaches New 1-Year Low – Time to Sell?

Inspire Medical Systems, Inc. (NYSE:INSP) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $43.03 and last traded at $43.3570, with a volume of 918050 shares. The stock had previously closed at $44.26.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Bank of America reaffirmed a “neutral” rating and issued a $53.00 price target on shares of Inspire Medical Systems in a report on Tuesday, May 5th. Mizuho decreased their price target on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Piper Sandler cut shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $85.00 to $55.00 in a report on Tuesday, May 5th. Evercore set a $55.00 price target on shares of Inspire Medical Systems in a report on Tuesday, May 5th. Finally, Wells Fargo & Company decreased their price target on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a report on Tuesday, May 5th. Four analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $85.00.

Inspire Medical Systems Stock Down 2.0%

The stock has a market cap of $1.25 billion, a price-to-earnings ratio of 9.66, a price-to-earnings-growth ratio of 4.57 and a beta of 0.83. The stock’s 50 day moving average price is $55.22 and its two-hundred day moving average price is $78.44.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts predict that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.

Institutional Trading of Inspire Medical Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in INSP. Wellington Management Group LLP acquired a new stake in shares of Inspire Medical Systems in the fourth quarter worth $203,929,000. M&T Bank Corp purchased a new position in Inspire Medical Systems in the fourth quarter valued at $85,871,000. Deerfield Management Company L.P. increased its holdings in Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after buying an additional 907,694 shares in the last quarter. Morgan Stanley increased its holdings in Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after buying an additional 809,121 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. purchased a new position in Inspire Medical Systems in the fourth quarter valued at $61,619,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.